Evidence map›Paper›PMID 38976087›Full record

ArticleAnnals of nuclear medicine2024

Novel technetium-99m-labeled bivalent PSMA-targeting probe based on hydroxamamide chelate for diagnosis of prostate cancer.

Yoichi Shimizu, Masato Ando, Hiroyuki Watanabe, Masahiro Ono

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of nuclear medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yoichi Shimizu *Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, 46-29, Yoshida Shimoadachi-Cho, Sakyo-Ku, Kyoto, 606-8501, Japan. yoichis@kuhp.kyoto-u.ac.jp.ORCID http://orcid.org/0000-0003-2831-3597
Masato Ando *Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, 46-29, Yoshida Shimoadachi-Cho, Sakyo-Ku, Kyoto, 606-8501, Japan.
Hiroyuki WatanabeDepartment of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, 46-29, Yoshida Shimoadachi-Cho, Sakyo-Ku, Kyoto, 606-8501, Japan.
Masahiro OnoDepartment of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, 46-29, Yoshida Shimoadachi-Cho, Sakyo-Ku, Kyoto, 606-8501, Japan. ono@pharm.kyoto-u.ac.jp.

Funding

the Japan Agency for Medical Research and Development 20ck0106426h0003the Japan Agency for Medical Research and Development JP24ama221604
6 · The paper itself

Abstract

objectiveProstate-specific membrane antigen (PSMA) is a well-known biomarker of prostate cancer. Previously, our group reported that the succinimidyl-cystatin-urea-glutamate (SCUE) moiety has a high affinity for PSMA. In this study, we developed the novel technetium-99m-labeled PSMA-targeting probe "[

methodsHam-SCUE was synthesized by a one-step reaction with Ham-Mal and cysteine-urea-glutamine. Then, Ham-SCUE was reacted with [

results[

conclusion[

Indexed as

Antigens, SurfaceGlutamate Carboxypeptidase IIProstatic NeoplasmsAnimalsCell Line, TumorChelating AgentsHumansIsotope LabelingMaleMiceOrganotechnetium CompoundsRadiochemistryTechnetiumTissue DistributionTomography, Emission-Computed, Single-PhotonAntigens, SurfaceChelating AgentsFOLH1 protein, humanGlutamate Carboxypeptidase IIOrganotechnetium CompoundsTechnetium99mTc-labeled bivalent ligand probesHydroxamamidePSMATechnetium-99m

Identifiers

PMID38976087

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.